Tirzepatide

Mechanism of Action

Tirzepatide is an investigational drug that is being developed for the treatment of type 2 diabetes. It is a dual-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) and glucose-dependent insulinotropic polypeptide receptor agonist (GIPRA) compound.

The mechanism of action of tirzepatide is based on its dual agonism of both the GLP-1 and GIP receptors, which leads to improved glucose control and reduction in body weight. By stimulating the GLP-1 receptor, tirzepatide enhances insulin secretion in a glucose-dependent manner, slows gastric emptying, and reduces food intake, leading to improved glycemic control. By stimulating the GIP receptor, tirzepatide enhances glucose-dependent insulin secretion, which contributes to improved glucose control.

Overall, the combination of GLP-1RA and GIPRA effects provides a potent and comprehensive approach to glucose control and weight reduction in individuals with type 2 diabetes.

Indication

Tirzepatide is an investigational drug that is being developed for the treatment of type 2 diabetes. It is a dual-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) and glucose-dependent insulinotropic polypeptide receptor agonist (GIPRA) compound. However, it is expected that tirzepatide will be used as a treatment option for individuals with type 2 diabetes who are inadequately controlled with current glucose-lowering medications, such as metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, or basal insulin. The potential benefits of tirzepatide in these individuals include improved glycemic control and reduction in body weight.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Tirzepatide API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Tirzepatide API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.